Dr. Lutzky is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
1475 NW 14th Ave
Miami, FL 33125Phone+1 305-689-6500Fax+1 305-689-6565
Summary
- Jose Lutzky, M.D., is a triple board-certified hematologist and oncologist at Sylvester Comprehensive Cancer Center. At Sylvester, Dr. Lutzky works as part of a multidisciplinary team of cancer experts and researchers. He earned his medical degree from Universida de Federal do Rio Grande do Sul. Dr. Lutzky is fluent in Spanish and Portuguese.
Clinical Expertise
- Melanoma and cutaneous malignancies
Education & Training
- New York Presbyterian Hospital (Columbia Campus)Fellowship, Hematology and Medical Oncology, 1985 - 1988
- Mount Sinai Medical Center of FloridaResidency, Internal Medicine, 1982 - 1985
- Federal University of Rio Grande do Sul School of MedicineClass of 1980
Certifications & Licensure
- FL State Medical License 1984 - 2026
- CA State Medical License 1989 - 2025
- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Hematology
- American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- America's Top Doctors Castle Connolly, 2020
- America's Top Doctors for Cancer Castle Connolly, 2020
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2013
- Join now to see all
Clinical Trials
- Study of a Drug [DCVax®-L] to Treat Newly Diagnosed GBM Brain Cancer Start of enrollment: 2006 Dec 01
- Rituximab and/or Lenalidomide in Treating Patients With Follicular Non-Hodgkin's Lymphoma That is Not Refractory to Rituximab Start of enrollment: 2006 Mar 01
- Imatinib Mesylate in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed by Surgery Start of enrollment: 2007 Apr 01
- Join now to see all
Publications & Presentations
PubMed
- Combined PD-1 and CTLA-4 Blockade in an International Cohort of Patients with Acral Lentiginous Melanoma.Erin McGillivray, Karam Ashouri, Eftychia Chatziioannou, Jesús Antonio Ocejo Gallegos, Jabra Zarka
The British Journal of Dermatology. 2024-10-23 - Meeting Report From the 2023 Cure Ocular Melanoma (CURE OM) Global Science Meeting, Philadelphia, PA, November 2023.Rino S Seedor, Andrew E Aplin, Corine Bertolotto, Richard D Carvajal, Nigel Deacon
Pigment Cell & Melanoma Research. 2024-10-09 - Is primary breast melanoma a true pathological entity? The argument against it.Alexis R Narvaez-Rojas, Samantha Linhares, Shaina Sedighim, Kyle Daniel Klingbeil, Clara Milikowski
Heliyon. 2024-09-30
Journal Articles
- Association of BRAF V600E/K Mutation Status and Prior BRAF/MEK Inhibition with Pembrolizumab Outcomes in Advanced MelanomaIgor Puzanov, Kim A Margolin, Jose Lutzky, Ahmad Tarhini, Nageatte Ibrahim, JAMA Oncology
Authored Content
- Association of BRAF V600E/K Mutation Status and Prior BRAF/MEK Inhibition with Pembrolizumab Outcomes in Advanced MelanomaJuly 2020
- Association of BRAF V600E/K Mutation Status and Prior BRAF/MEK Inhibition with Pembrolizumab Outcomes in Advanced MelanomaJuly 2020
Press Mentions
- Northwest Biotherapeutics: Data Is Done, Just Wait for ApprovalNovember 23rd, 2022
- New Immunotherapy Drug Combo Approved for Metastatic MelanomaApril 11th, 2022
- Watch Out for Those Tanning Beds — They’re Linked to Skin CancerMay 27th, 2017
- Join now to see all
Professional Memberships
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: